Back to Posts

Regulatory Sciences Blog Posts

November 2, 2022 Regulatory Sciences

Ban on Titanium Dioxide (E171) on the EU Food Market:...

Use of Titanium Dioxide in the EU Food Market In 2021, the…

Read Blog Post
October 25, 2022 Regulatory Sciences

FDA Accelerated Approval Pathway: A Potential Missed Opportunity for Sponsors

The accelerated approval provisions of FDASIA in section 506(c) of the FD&C…

Read Blog Post
October 19, 2022 Regulatory Sciences

What You Need to Know About Developing Vaccines

An unlikely beacon of hope from the otherwise disastrous Covid pandemic, may…

Read Blog Post
October 12, 2022 Regulatory Sciences

Prescription Drug User Fee Act (PDUFA) VII and Type D...

For those who have been awaiting Congressional reauthorization of PDUFA, the wait…

Read Blog Post
September 27, 2022 Regulatory Sciences

What You Need to Know About CBER Pre-IND Meetings

The FDA provides several opportunities to hold meetings with Sponsors to gain…

Read Blog Post
September 20, 2022 Regulatory Sciences

CAR-T Cells: Challenges, Lessons Learned, and Guidance for the Clinical...

It comes as no surprise to any pharmaceutical or biotech company that…

Read Blog Post
September 14, 2022 Regulatory Sciences

How to Comply with the Nitrosamine Regulations for Your New...

Introduction: Are you in the development phase for your medicinal product? Have…

Read Blog Post
August 26, 2022 Regulatory Sciences

FDA Announces Availability of Multiple Draft Guidances – Drug Information...

Today, FDA announced the availability of the following draft guidances for industry,…

Read Blog Post

Your Business has Complex Challenges. ProPharma Group has Exceptional Solutions.

We partner with pharmaceutical, biotechnology, and medical device clients to tackle complex challenges. Contact us to learn how our experienced team can help ensure regulatory and development success throughout the product lifecycle.

Interested in gaining an industry edge? Let us help you stay up to date.


All fields are required.
There was a problem with your submission. Errors have been highlighted below.